Global Cancer Monoclonal Antibodies Market &Clinical Trial Insight 2024

 “Global Cancer Monoclonal Antibodies  Market & Clinical Trial Insight 2024” Report Highlights: 

• Significance for Monoclonal Antibodies for Cancer Treatment
• Global Cancer Monoclonal Antibodies Market Overview
• Global Cancer Monoclonal Antibodies Pipeline by Phase & Indication
• Global Cancer Monoclonal Antibodies Pipeline: 697 mAb
• Marketed Cancer Monoclonal Antibodies: 60
• Global Cancer Monoclonal Antibodies Market Opportunity: US$ 140 Billion

Download Report:

http://www.pnspharma.com/buy-report.php?reporttitle=Global-Cancer-Monoclonal-Antibodies–Market-%26Clinical-Trial-Insight-2024

The recent years have witnessed the emergence of monoclonal antibodies, which has the potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the past decades, the researchers have increased their learning about the human body’s immune system, which has led to the achievement of significant number of regulatory milestones during this period. The use of mAbs for treating cancer has increased significantly. The rising market availability of these agents has enabled the pharmaceutical companies to develop novel combination approaches which have the capability to provide even greater insight into the body’s immune system so as to develop more efficient mAbs.

 

Report TOC

 

1. Introduction to Monoclonal Antibodies

1.1 History of Development

1.2 Working of Monoclonal Antibodies

 

2. Monoclonal Antibodies Classification

2.1 Naked Monoclonal Antibodies

2.2 Conjugated Monoclonal Antibodies

2.2.1 Radiolabeled Antibodies

2.2.2 Chemolabeled Antibodies

2.2.3 Immunotoxins

 

3. Monoclonal Antibodies Mechanisms

3.1 Tumor Antigens as Targets of Antibodies

3.2 Development of Antibodies for Clinical Purposes

3.3 Complement Dependent Cytotoxicity (CDC)

3.4 Signal Transduction Changes

 

4. Significance for Monoclonal Antibodies for Cancer Treatment

 

5. Global Cancer Monoclonal Antibodies Market Overview

5.1 Current Market Scenario

5.2 Clinical Pipeline Insight

 

6. Global Cancer Monoclonal Antibodies Market Future Outlook

 

7. Global – Bladder Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

7.1 Phase-I/II

7.2 Phase-II

7.3 Phase-III

 

8. Marketed Bladder Cancer Monoclonal Antibodies Clinical Insight

8.1 Durvalumab (Imfinzi)

 

9. Global – Blood Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

9.1 Unknown

9.2 Research

9.3 Preclinical

9.4 Clinical

9.5 Phase-I

9.6 Phase-I/II

9.7 Phase-II

9.8 Phase-III

9.9 Preregistration

 

10. Marketed Blood Cancer Monoclonal Antibodies Clinical Insight

10.1 Daratumumab (DARZALEX)

10.2 Ofatumumab (Arzerra)

10.3 Obinutuzumab (GAZYVA, Gazyva & Gazyvaro)

10.4 Blinatumomab (Blincyto)

10.5 Elotuzumab (Empliciti)

10.6 Mogamulizumab (Poteligeo)

10.7 Alemtuzumab (Campath, Lemtrada, MabCampath, MabKampat & Remniq)

10.8 Brentuximab Vedotin (Adcetris)

10.9 Inotuzumab Ozogamicin (BESPONSA & Besponsa)

10.10 Rituximab Biosimilar (AcellBia, Acellbia & USMAL)

10.11 Rituximab Biosimilar (Blitzima, Ritemvia, Truxima & Tuxella)

10.12 Rituximab Biosimilar (Rixathon & Riximyo)

10.13 Gemtuzumab Ozogamicin (Mylotarg)

10.14 Ibritumomab Tiuxetan (Zevalin & Zevamab)

10.15 Rituximab Biosimilar (REDDITUX, Reditux & Tidecron)

10.16 Rituximab Biosimilar (Novex)

10.17 Rituximab Biosimilar (CIMAbior & RituxCIM)

10.18 Rituximab/Hyaluronidase (MabThera SC, RITUXAN SC & Rituxan Hycela)

10.19 Rituximab Biosimilar (Zytux)

10.20 Rituximab Biosimilar (RituxiRel, Toritz & Toritz RA)

10.21 Rituximab Biosimilar (Maball)

10.22 Rituximab Biosimilar (Kikuzubam)

10.23 Rituximab Biosimilar (Mabtas)

 

11. Global – Breast Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

11.1 Unknown

11.2 Research

11.3 Preclinical

11.4 Phase-I

11.5 Phase-II

11.6 Phase-III

11.7 Preregistration

11.8 Registered

 

12. Marketed Breast Cancer Monoclonal Antibodies Clinical Insight

12.1 Trastuzumab Subcutaneous (Herceptin SC)

12.2 Pertuzumab (Omnitarg & Perjeta)

12.3 Trastuzumab Biosimilar (CANMAb, Hertraz, Ogivri & Zedora)

12.4 Trastuzumab Emtansine (Kadcyla)

12.5 Trastuzumab Biosimilar (Vivitra)

 

13. Global Bone Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

13.1 Phase-III

 

14. Marketed Bone Cancer Monoclonal Antibodies Clinical Insight

14.1 Denosumab (PRALIA, Prolia, Ranmark & Xgeva)

 

15. Global – Brain Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

15.1 Preclinical

15.2 Phase-I/II

15.3 Phase-III

15.4 Registered

 

16. Marketed Brain Cancer Monoclonal Antibodies Clinical Insight

16.1 Dinutuximab (Unituxin)

 

17. Global – Cervical Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

17.1 Phase-I/II

 

18. Global – Colorectal Cancer Monoclonal Antibodies Clinical pipeline by Company & Phase

18.1 Unknown

18.2 Preclinical

18.3 Phase-I

 

19. Global – Head and Neck Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

19.1 Preclinical

19.2 Phase-I/II

19.3 Phase-III

 

20. Global – Liver Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

20.1 Phase-II

 

21. Global – Kidney Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

21.1 Preclinical

21.2 Phase-II

21.3 Phase-III

 

22. Global – Skin Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

22.1 Research

22.2 Preclinical

22.3 Phase-I

22.4 Phase-I/II

22.5 Phase-II/III

22.6 Phase-III

22.7 Preregistration

 

23. Marketed Skin Cancer Monoclonal Antibodies Clinical Insight

23.1 Avelumab (BAVENCIO)

23.2 Olaratumab (Lartruvo)

 

24. Global – Stomach Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

24.1 Preclinical

24.2 Phase-I/II

24.3 Phase-II

24.4 Phase-III

24.5 Preregistration

 

25. Marketed Stomach Cancer Monoclonal Antibodies Clinical

25.1 Bevacizumab Biosimilar (Bevax)

25.2 Cetuximab Biosimilar – CinnaGen

25.3 Bevacizumab Biosimilar (Cizumab)

 

 

26. Global – Lung Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

26.1 Research

26.2 Clinical

26.3 Phase-I

26.4 Phase-I/II

26.5 Phase-II

26.6 Phase-II/III

26.7 Phase-III

26.8 Preregistration

26.9 Registered

 

27. Marketed Lung Cancer Monoclonal Antibodies Clinical Insight

27.1 Necitumumab (Portrazza)

27.2 Iodine I 131 Derlotuximab Biotin (Cotara)

27.3 Bevacizumab Biosimilar (Bryxta)

27.4 Racotumomab (Vaxira)

27.5 Racotumomab (Vaxira)

27.6 Tc 99m Nofetumomab Merpentan (VerLuma)

 

28. Global – Ovarian Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

28.1 Research

28.2 Preclinical

28.3 Phase-I

28.4 Phase-I/II

28.5 Phase-II

 

29. Global – Pancreatic Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

29.1 Preclinical

29.2 Phase-I

29.3 Phase-I/II

29.4 Phase-II

 

30. Marketed Pancreatic Cancer Monoclonal Antibodies Clinical Insight

30.1 Gemcitabine elaidate companion diagnostic – Ventana Medical Systems/Clovis Oncology

 

31. Global – Prostate Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

31.1 Preclinical

31.2 Phase-II

 

32. Global – Multiple Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

32.1 Unknown

32.2 Research

32.3 Preclinical

32.4 Clinical

32.5 Phase-I

32.6 Phase-I/II

32.7 Phase-II

32.8 Phase-II/III

32.9 Phase-III

32.10 Registered

 

33. Marketed Multiple Cancer Monoclonal Antibodies Clinical Insight

33.1 Cetuximab (Erbitux)

33.2 Nivolumab (Opdivo)

33.3 Bevacizumab (Avastin)

33.4 Trastuzumab (Herceptin)

33.5 Atezolizumab (TECENTRIQ)

33.6 Rituximab (MabThera & Rituxan)

33.7 Ramucirumab (Cyramza, Sairamza & Silamza)

33.8 Trastuzumab Biosimilar (Herzuma)

33.9 Pembrolizumab (Keytruda)

33.10 Pembrolizumab Companion Diagnostic (PD-L1 IHC 22C3 pharmDx)

33.11 Ipilimumab (Yervoy)

33.12 Trastuzumab Biosimilar (BIOMAb EGFR, CIMAher, Cimaher, Taixinsheng, TheraCIM, Theraloc & VECTHIX)

33.13 Nimotuzumab (BIOMAb EGFR, CIMAher, Cimaher, Taixinsheng, TheraCIM, Theraloc & VECTHIX)

33.14 Bevacizumab Biosimilar (KRABEVA)

33.15 Bevacizumab Biosimilar (Mvasi)

33.16 Trastuzumab Biosimilar (AryoTrust)

33.17 Satumomab (OncoScint CR/OV)

 

34. Competitive Landscape

34.1 Abbvie

34.2 Amgen

34.3 Bayer HealthCare

34.4 Biogen Idec

34.5 Eli Lilly

34.6 Genmab

34.7 Gilead Sciences

34.8 GlaxoSmithKline

34.9 Novartis

34.10 Pfizer

34.11 Roche

34.12 Seattle Genetics